Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Histone deacetylase (HDAC) enzymatic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM). Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM. In the present study, we investigated the preclinical ac...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Santo, Loredana, Hideshima, Teru, Kung, Andrew L., Tseng, Jen-Chieh, Tamang, David, Yang, Min, Jarpe, Matthew, van Duzer, John H., Mazitschek, Ralph, Ogier, Walter C., Cirstea, Diana, Rodig, Scott, Eda, Homare, Scullen, Tyler, Canavese, Miriam, Bradner, James, Anderson, Kenneth C., Jones, Simon S., Raje, Noopur
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2012
Materias:
Lymphoid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3337713/
https://ncbi.nlm.nih.gov/pubmed/22262760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-10-387365
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares